HemaCare Co. (OTCMKTS:HEMA – Get Free Report) rose 0.6% during trading on Thursday . The company traded as high as $25.31 and last traded at $25.31. Approximately 5,400 shares were traded during trading, a decline of 86% from the average daily volume of 39,950 shares. The stock had previously closed at $25.16.
HemaCare Stock Up 0.6%
The business’s 50-day moving average price is $25.31 and its 200-day moving average price is $25.31.
HemaCare Company Profile
HemaCare Corporation is a specialty life sciences company that supplies primary human blood and bone marrow-derived cells for research, drug development and medical device evaluation. The company’s product portfolio includes peripheral blood mononuclear cells (PBMCs), buffy coats, hematopoietic stem and progenitor cells, whole blood, bone marrow aspirates and custom-processed cell fractions. These offerings are designed to support preclinical studies, translational research and in vitro assays across immunology, hematology, oncology and regenerative medicine applications.
In addition to off-the-shelf cell products, HemaCare provides custom cell isolation services, donor screening and logistics solutions tailored to the needs of pharmaceutical, biotechnology and academic customers.
See Also
- Five stocks we like better than HemaCare
- Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem
- These 3 Software Stocks Are Buying Back Shares Hand Over Fist
- Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%
- MongoDB’s AI Advantage Is Starting to Show Up in Results
Receive News & Ratings for HemaCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HemaCare and related companies with MarketBeat.com's FREE daily email newsletter.
